"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
Aside from possible ovarian hyperstimulation (see WARNINGS), little is known concerning the consequences of acute overdosage with menotropins.
Repronex® (menotropins for injection) is contraindicated in women who have:
- A high FSH level indicating primary ovarian failure.
- Uncontrolled thyroid and adrenal dysfunction.
- An organic intracranial lesion such as a pituitary tumor.
- The presence of any cause of infertility other than anovulation unless they are candidates for in vitro-fertilization.
- Abnormal bleeding of undetermined origin.
- Ovarian cysts or enlargement not due to polycystic ovary syndrome.
- Prior hypersensitivity to menotropins.
- Repronex® (menotropins for injection) is not indicated in women who are pregnant. There are limited human data on the effects of menotropins when administered during pregnancy.
Last reviewed on RxList: 10/9/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Repronex Information
Repronex - User Reviews
Repronex User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.